Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.
Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.
Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.